Carbamazepine activates private self and viral reactive TCRs through a drug-permissive HLA-B cleft
Open Access
- 19 August 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1919927
Abstract
Introduction: Carbamazepine (CBZ) can cause severe cutaneous adverse reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis, and is strongly associated with HLA risk alleles. However, HLA genotype alone incompletely predicts clinical risk. Adverse drug reactions depend on drug-peptide-HLA conformation, immuno-regulatory cell interactions and the presence of drug-specific TCR clonotypes in susceptible patients. An unresolved question is whether patients that develop a specific drug reaction harbor the same drug-specific TCR (public TCR) or generate patient unique TCRs (private TCR). Methods: To address this controversy we expressed four published CBZ-associated TCRs including two public and two private clonotypes, in TCR-null TG40 cells and tested activation using monoallelic 721.221 APCs expressing HLA-B*15:02, HLA-B*57:01, HLA-B*58:01, or HLA-B*58:01(TE→MA), as well as HLA-transgenic/MHC I-deficient murine splenic APCs. T-cell activation was quantified by PD-1, CD69, and 4-1BB, while LC-MS/MS immunopeptidomics/MAPPs was used to assess drug effects on the peptide repertoire. CBZ docking was applied to define drug-peptide-MHC-TCR interactions in a drug reactive peptide specific TCR. Results and discussion: Public TCRs showed no CBZ-dependent activation, whereas private TCRs displayed dose-dependent, HLA class I-dependent responses supported by HLA-B*15:02 and unexpectedly HLA-B*57:01, but not HLA-B*58:01. Amino acid substitutions to HLA-B*58:01 (T45-E46 to M45-A46) mapped drug presentation to restore CBZ responsiveness without altering HLA expression. CBZ did not detectably induce broad abacavir-like peptide motif alterations but amplified HIV Gag KF11 peptide-driven T cell activation in an allele- and mutation-dependent manner. Modeling predicted a candidate CBZ accessible region beneath the peptide near HLA Met67, HLA Tyr9, and a conserved CDR3α tyrosine providing a plausible structural rationale for allele and clonotype-dependent activation. These findings support a model in which CBZ potentiates binding of selected peptide-HLA-TCR interfaces governed by HLA cleft architecture and clonotype-level TCR sensitivity. This mechanism explains why HLA screening alone incompletely predicts CBZ-SJS/TEN risk and highlights peptide-HLA-TCR functional context as a potential determinant for improved risk assessment and mechanistic drug hypersensitivity testing.Keywords
This publication has 54 references indexed in Scilit:
- Updates on the immunopathology and genomics of severe cutaneous adverse drug reactionsJournal of Allergy and Clinical Immunology, 2023
- Current perspective of the etiopathogenesis of delayed-type, and T-cell–mediated drug-related skin diseasesJournal of Allergy and Clinical Immunology, 2020
- Clinical Pharmacogenetics Implementation Consortium Guideline forHLAGenotype and Use of Carbamazepine and Oxcarbazepine: 2017 UpdateClinical Pharmacology & Therapeutics, 2018
- Evolving models of the immunopathogenesis of T cell–mediated drug allergy: The role of host, pathogens, and drug responseJournal of Allergy and Clinical Immunology, 2015
- Relationship Between theHLA-B*1502Allele and Carbamazepine-Induced Stevens-Johnson Syndrome and Toxic Epidermal NecrolysisJAMA Dermatology, 2013
- Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndromeJournal of Allergy and Clinical Immunology, 2011
- Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in KoreansEpilepsy Research, 2011
- Immune pathomechanism of drug hypersensitivity reactionsJournal of Allergy and Clinical Immunology, 2011
- HLA-B∗1502–bound peptides: Implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndromeJournal of Allergy and Clinical Immunology, 2007
- Activation of T cells by carbamazepine and carbamazepine metabolitesJournal of Allergy and Clinical Immunology, 2006